|
⚲
|
| Keyboard |
| Paradigm Biocapital Advisors LP
✚
|
|
|---|---|
| CRD # | 312544 |
| SEC # | 801-120338 |
| CIK # | 0001855655 |
| AUM | 4,469.2 M (2026-05-27) |
| Employees | 11 (55% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-970-2568 |
| Address | 520 Fifth Avenue New York, NY 10036 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (5/27/2026) [Brochure] |
|---|
Item 5: Fees and Compensation As an investment adviser to the Funds, as further described in the Offering Documents, PBCA receives an annual management fee generally equal to 1.5%. The management fees are paid by the Master Fund monthly in advance on the first day of each month, depending upon the net asset value of the Funds and each particular investment by an Investor in the Funds. Management fees are generally pro-rated for partial periods. Once paid, management fees are non-refundable. The Firm or its affiliates may reduce, waive or calculate differently the management fee for certain Investors, including but not limited to, members, employees and affiliates of PBCA. Other Fees and Expenses The Feeder Funds will bear their own expenses and their pro rata share of the Master Fund’s expenses, including, without limitation, Operating Expenses (as hereinafter defined) and Organizational Expenses (as hereinafter defined), and shall reimburse PBCA, the General Partner or any of their respective affiliates for any Operating Expenses and Organizational Expenses incurred by such persons. Organizational and Initial Offering Expenses The Feeder Funds will pay or reimburse PBCA, the General Partner, and/or affiliates of PBCA for all organizational and initial offering expenses of the Funds, including, but not limited to, legal and accounting fees, printing and mailing expenses and government filing fees (including “blue sky” filing fees). The Funds’ organizational and initial offering expenses may be, for accounting purposes, capitalized and amortized by the Funds for up to 60 months from the date the Funds commence operations. Amortization of such expenses is a divergence from U.S. generally accepted accounting principles (“GAAP”). In certain circumstances, this divergence may result in a qualification of the Funds’ annual audited financial statements. In such instances, the Funds may elect to: (i) avoid the qualification by recognizing the unamortized expenses, or (ii) make GAAP-conforming changes for financial reporting purposes, but capitalize and amortize expenses for purposes of calculating the Funds’ Net Asset Value (resulting in a divergence in fiscal year-end Net Asset Values reported in the Funds’ financial statements, and as otherwise applicable under the provisions of the Offering Documents). If the Funds capitalize and amortize such expenses and are then terminated within 60 months of their commencement, any unamortized expenses will be recognized. If an Investor in a Fund makes a withdrawal prior to the end of the period during which the particular Fund is capitalizing and amortizing expenses, the Fund may, but is not required to, accelerate a proportionate share of the unamortized expenses based upon the amount being withdrawn and reduce withdrawal proceeds accordingly. Operating Expenses Each Fund will incur its own expenses. The expenses and results of operations of the Master Fund will be allocated to the Feeder Funds and the other Investors in the Master Fund, in proportion to the capital accounts of the Feeder Funds and such other investors in the Master Fund, from time to time. The Funds will pay or reimburse PBCA, the General Partner, and/or affiliates of PBCA for: (i) all expenses incurred in connection with the ongoing offer and sale of interests, including, but not limited to, printing of the Offering Documents and exhibits, marketing expenses and documentation of performance and the admission of Investors, (ii) all operating expenses of the Funds, such as tax preparation fees, governmental fees and taxes, administration fees paid to the Fund Administrator providing services to the Funds, costs of communications with Investors, and ongoing legal, accounting, auditing, bookkeeping, consulting and other professional fees and expenses, (iii) all research, trading and investment-related costs and expenses (e.g., brokerage commissions, research fees, margin Paradigm BioCapital Advisors LP Form ADV Part 2A interest, expenses related to short sales, custodial fees, bank service fees, and clearing and settlement charges) of the Funds, (iv) technology-related costs and expenses, including, but not limited to, software licenses, data feeds and colocation expenses, (v) all expenses related to attending any conference or seminar related to alternative investments (e.g., registration, transportation, accommodation or meal expenses), (vi) regulatory and other filing fees and expenses, and compliance costs and expenses of the Funds, including, but not limited to, all fees and expenses incurred by PBCA and/or its affiliates directly in connection with examinations by the SEC and other regulatory authorities that are attributable to the Funds, as well as fees and expenses associated with the completion of regulatory filings that are attributable to the Funds (including, without limitation, Form PF filings), (vii) travel expenses related to meeting with management teams, or related to any of the other categories of expenses set forth herein, (viii) any costs and expenses incurred by the Funds in connection with converting from a “feeder fund” as part of a master-feeder structure into a stand- alone fund, (ix) director and officer liability insurance or other insurance premiums for any principal or employee of the Funds, PBCA, the General Partner, or any affiliates of PBCA, (x) all fees and other expenses incurred in connection with the investigation, prosecution or defense of any claims, assertion of rights or pursuit of remedies, by or against the Funds, including, without limitation, professional and other advisory and consulting expenses, and (xi) any and all costs and expenses incurred in connection with the dissolution, winding-up, or termination of one or more of the Funds. Each of PBCA, the General Partner, or any affiliates of PBCA, in its sole discretion, may from time to ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (5/27/2026) [Brochure] |
|---|
Item 7: Types of Clients Paradigm BioCapital Advisors LP Form ADV Part 2A Currently, PBCA provides investment advice to the Funds and the SMA. Each of the Funds set forth the eligibility criteria and minimum investment requirements for Investors. Initial and additional subscription minimums are disclosed in the Offering Documents for each Fund, which may be waived at the discretion of PBCA. Each Investor generally must be (i) an “accredited investor”, as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and (ii) a “qualified client”, as defined in the Advisers Act. The subscription agreement contains representations and questionnaires relating to these qualifications. The minimum initial investment that will be accepted from a prospective Investor into the Feeder Funds is $5,000,000. The minimum additional capital contribution that will be accepted from an existing Investor is $250,000. In each case, PBCA has discretion to accept lesser amounts. In addition to providing investment management services to the Funds, PBCA may advise other clients in the future that may include additional private funds or separately managed accounts. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 0.6 | ||
| Nuvalent Inc | 0.5 | ||
| Vaxcyte Inc | 0.3 | ||
| Edgewise Therapeutics Inc | 0.2 | ||
| Genmab A/S | 0.2 | ||
| Insmed Inc | 0.2 | ||
| Tarsus Pharmaceuticals Inc | 0.2 | ||
| Belite Bio Inc | 0.2 | ||
| Erasca Inc | 0.2 | ||
| Olema Pharmaceuticals Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Paradigm Biocapital International Fund Ltd | [2021-06-23] | 105.3 M | 4,004.1 M |
| Filed 2025-04-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 4.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.5 |
| Total | 4 | 4.5 |
| By Discretionary | ||
| Discretionary | 4 | 4.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 4.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 4.0 | |
| United States Persons | 0.5 | |
| Total | 4 | 4.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Senai Asefaw | Executive Officer | 3 | 2 | |
| Paradigm Biocapital GP LLC | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001855655] | |
| 3 | [0001855655] | |
| 4 | [0001855655] | |
| SC 13G | [0001855655] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300I649YOM8XI0E93 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Olema Pharmaceuticals Inc | |
| Asefaw Senai | |
| Paradigm BioCapital Advisors GP LLC | |
| Paradigm BioCapital International Fund Ltd | |
| Paradigm Biocapital Advisors LP |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Olema Pharmaceuticals Inc OLMA
Common Stock, par value $0.0001 per share
|
2024-08-01 | Sell | 529,501 | $14.92 | 7,900,155 |
|
Olema Pharmaceuticals Inc OLMA
Common Stock, par value $0.0001 per share
|
2024-08-01 | Sell | 1,870,499 | $14.92 | 27,907,845 |
|
Olema Pharmaceuticals Inc OLMA
Common Stock, par value $0.0001 per share
|
2023-12-06 | Buy | 100,000 | $11.60 | 1,160,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Dwight Securities Management LLC
✚
|
FL | 4,555.8 M |
|
Conifer Management LLC
✚
|
NY | 4,531.5 M |
|
Hawk Ridge Capital Management LP
✚
|
CA | 4,528.0 M |
|
Performa Limited US LLC
✚
|
SC | 4,491.2 M |
|
Elementum Advisors LLC
✚
|
IL | 4,475.9 M |
|
Bluespruce Investments LP
✚
|
IL | 4,454.3 M |
|
Valley Forge Capital Management LP
✚
|
FL | 4,447.8 M |
|
Locust Wood Capital Advisers LLC
✚
|
NY | 4,395.9 M |
|
AQR Arbitrage LLC
✚
|
CT | 4,384.1 M |
|
RWC Asset Advisors US LLC
✚
|
FL | 4,380.3 M |